CA
NZ
UK
AU
IND
US
The story of T2 Biosystems, Inc (OTC:TTOO) is no longer about the next catalyst, it is about the end of the road. The former medical-diagnostics company, once listed on the Nasdaq, has beenDelistedand is proceeding with an orderly wind-down of its operations.
Tvardi Therapeutics, Inc (NASDAQ:TVRD) is a clinical-stage biotech still recovering from a setback that reshaped itsInvestmentcase. After its lead program disappointed in a closely watched lung-disease trial in late 2025, the stock reset dramatically lower, and its story now hinges on a different indication …
Robotic surgery has long promised to reshape how doctors treat the heart, and Stereotaxis, Inc (NYSE American:STXS) sits close to the center of that idea. The company builds magnetic navigation systems that steer catheters through the cardiovascular system with a precision human hands struggle …
A busy summer of clinical and financing announcements has kept 60 Degrees Pharmaceuticals, Inc (NASDAQ:SXTP) in the conversation among small-cap biotech watchers, even as the shares trade below a dollar. The Washington, D.C.-area infectious-disease specialist is best known for antiparasitic work, and it heads …
Once a well-funded cancer-drug developer, Syros Pharmaceuticals has faded from public markets after a pivotal trial setback. Syros Pharmaceuticals (OTC: SYRS) now changes hands for a fraction of a cent, a shadow of the Nasdaq-listed biotech that once carried a nine-figure valuation. The quiet …
Few small-capMedTechnames have had a more eventful 2026 than TELA Bio, Inc (NASDAQ:TELA), a commercial-stage soft-tissue reconstruction company that spent the summer overhauling itsLeadershipand attacking its cost base. Trading onNasdaqunder the ticker TELA, the shares slipped below a dollar, a level that heightens bothVolatilityand …
The ticker TLOG still generates a sub-penny quote, which can create the impression of a company biding its time before a comeback. The reality is starkly different. TetraLogic Pharmaceuticals Corporation (OTC:TLOG) ceased to be a normal, reporting public company almost a decade ago, havingDelistedfrom …
Statera Biopharma, Inc. (OTC:STAB) entered the public markets with an ambitious immunotherapy pipeline and a portfolio of drug candidates aimed at autoimmune disease, radiation injury and cancer. Today the reality is starker: its most valuable asset has been licensed away to another company.
● STERIS has quietly become one of the most dependable operators in healthcare infrastructure, and in September 2026 the stock sits near $215 with a marketCapitalizationnorth of $20 billion on the New York Stock Exchange.
Priced at a fraction of a cent, Stemtech Corporation (OTC:STEK) is about as far down the market-cap ladder as a listed company can go. The wellness and nutrition marketer, which sells plant-based stem-cell support supplements, trades on the OTC Pink tier at roughly $0.0001 …
Please wait processing your request...